Entering text into the input field will update the search result below

Palatin +28.9%; FDA AdComm recommends approving HSDD drug

Jun. 04, 2015 7:09 PM ETPalatin Technologies, Inc. (PTN) StockBy: Eric Jhonsa, SA News Editor13 Comments
  • The FDA Advisory Committee has recommended approving flibanserin, a Sprout Pharmaceuticals drug meant to treat women with hypoactive sexual desire disorder (HSDD). The media has often referred to flibanserin as a female Viagra.
  • Palatin (NYSE:PTN), which is currently taking enrollments for Phase 3 trials of its bremelanotide HSDD drug, has jumped to $1.16 in AH trading.

Recommended For You

About PTN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PTN--
Palatin Technologies, Inc.